间氯苯氧乙酸 | 588-32-9

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 间氯苯氧乙酸
• 中文别名: 3-氯苯氧基乙酸；3-氯苯氧乙酸
• 英文名称: 3-chlorophenoxyacetic acid
• 英文别名: 2-(3-chlorophenoxy)acetic acid；m-chlorophenoxyacetic acid
• CAS: 588-32-9
• 化学式: C₈H₇ClO₃
• mdl: MFCD00015850
• 分子量: 186.595
• InChiKey: XSBUXVWJQVTYLC-UHFFFAOYSA-N

物化性质

• 熔点：
  106-111 °C
• 沸点：
  266.91°C (rough estimate)
• 密度：
  1.3245 (rough estimate)
• 颜色/状态：
  Crystals from water
• 溶解度：
  0.01 M
• 蒸汽压力：
  3.2X10-4 mm Hg at 25 °C (est)
• 解离常数：
  pKa = 3.07
• 稳定性/保质期：
  稳定性和反应性： 要避免的物料：氧化物。 要分解的产品：一氧化碳和二氧化碳、氯化氢。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

ADMET

代谢

产生产生5-氯-2-羟基苯氧基乙酸，可能是在曲霉中。/来自表格/

YIELDS 5-CHLORO-2-HYDROXYPHENOXYACETIC ACID PROBABLY IN ASPERGILLUS. /FROM TABLE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒病例。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 解毒与急救

如果在吸入喷雾期间或之后出现任何疾病症状，请将受害者与该物质接触至少2到3天。只有在实践有效的呼吸防护的情况下，才允许随后接触氯苯氧基化合物。/氯苯氧基化合物/

If any symptoms of illness occur during or following inhalation of spray, remove victim from contact with the material for at least 2 to 3 days. Allow subsequent contact with chlorophenoxy compounds only if effective respiratory protection is practiced. /Chlorophenoxy compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

用大量的清水冲洗眼睛10到15分钟。如果刺激持续存在，应进行眼科检查。如果摄入了大量氯苯氧基化合物，可能会自发呕吐。...给予静脉输液，以加速氯苯氧基化合物的排泄，并限制肾中毒素的浓度。理想的尿流量为4-6毫升/分钟。静脉输注生理盐水/葡萄糖已足以挽救那些入院前几小时饮用了2,4-D和灭草快的昏迷患者。注意：仔细监测尿蛋白和细胞、血尿素氮、血清肌酐、血清电解质以及液体摄入/排出，以确保肾功能未受损且不会发生液体超负荷。/氯苯氧基化合物/

Flush chemicals from eyes with copious amounts of clean water for 10 to 15 minutes. If irritation persists, an ophthalmologic examination should be performed. If substantial amounts of chlorophenoxy compounds have been ingested, spontaneous emesis may occur. ...Administer intravenous fluids to accelerate the excretion of chlorophenoxy compounds, and to limit concentration of the toxicant in the kidney. A urine flow of 4-6 mL/minute is desirable. Intravenous saline/dextrose has sufficed to rescue comatose patients who drank 2,4-D and mecoprop several hours before hospital admission. Caution: Monitor urine protein and cells, BUN, serum creatinine, serum electrolytes, and fluid intake/output carefully to ensure that renal function remains unimpaired and that fluid overload does not occur. /Chlorophenoxy compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

如果摄入，通常会发生自发呕吐。通常情况下，这可以像插管和灌洗一样有效地清空胃部。如果没有发生剧烈呕吐，应采取措施通过插胃管、抽吸和灌洗来清空胃部，并限制胃肠吸收，这需要在放置带气囊的气管内导管后进行。每隔2-4小时重复给予一半或更多原始剂量的活性炭可能有益。如果由于治疗延迟而未进行胃部抽吸和灌洗，且患者完全清醒，可口服给予活性炭和泻药。/氯苯氧基化合物/

If ... ingested, spontaneous emesis usually occurs. Ordinarily, this empties the stomach as effectively as intubation & lavage. If vigorous emesis has not occurred, measures should be taken to empty the stomach and limit gastrointestinal absorption by gastric intubation, aspiration, and lavage, following placement of a cuffed endotracheal tube. Repeated administration of charcoal at half or more the original dosage every 2-4 hours may be beneficial. If gastric aspiration and lavage is not performed due to delay in treatment, and if the patient is fully alert, administer charcoal, and laxative orally. /Chlorophenoxy compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

强制碱性利尿已被成功用于管理自杀性摄入氯苯氧基化合物，尤其是当早期启动时。通过在静脉溶液中添加碳酸氢钠来碱化尿液，可以显著加速2,4-D的排泄，并大幅增加灭草松的排泄。应保持尿液pH值在7.6到8.8之间。根据需要加入氯化钾以抵消钾的损失……。密切监测血清电解质，尤其是钾和钙，至关重要。当尿液中毒性物质的浓度非常高时，对肾脏可能存在一些风险，因此应仔细监测肾功能和液体平衡，因为氯苯氧基化合物被排出。在碱性利尿期间，严重中毒的患者可能会出现肾衰竭。…… /氯苯氧基化合物/

Forced alkaline diuresis has been used successfully in management of suicidal ingestions of chorophenoxy compounds, especially when initiated early. Alkalinizing the urine by adding sodium bicarbonate in the intravenous solution accelerates excretion of 2,4-D dramatically and mecoprop excretion substantially. Urine pH should be maintained between 7.6 and 8.8. Include potassium chloride as needed to offset potassium losses... . It is crucial to monitor serum electrolytes carefully, especially potassium and calcium. There may possibly be some hazard to the kidneys when urine concentrations of toxicant are very high, so the integrity of renal function and fluid balance should be monitored carefully as the chlorophenoxy compound is excreted. Renal failure has occured in patients with severe intoxication during alkaline diuresis. ... /Chlorophenoxy compounds/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S22,S36/37
• 危险类别码：
  R22
• 海关编码：
  2918990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  2811
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  贮存时，请将密闭容器密封后放置于阴凉、干燥处。

SDS

Name:	3-Chlorophenoxyacetic acid 98% Material Safety Data Sheet
Synonym:
CAS:	588-32-9

Section 1 - Chemical Product MSDS Name:3-Chlorophenoxyacetic acid 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
588-32-9	3-Chlorophenoxyacetic acid	98%	209-616-6

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 588-32-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 106 - 111 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7ClO3
Molecular Weight: 186.59

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 588-32-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chlorophenoxyacetic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 588-32-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 588-32-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 588-32-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  间氯苯氧乙酸 在 calcium(II) chloride dihydrate 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 以82%的产率得到
  参考文献：
  名称：

  基于苯氧乙酸的钙配位化合物：微波合成、热稳定性和对配体上氯取代基晶体结构的影响

  摘要：

  摘要 三种钙配位化合物 [Ca(CPA)(H2O)4]·(CPA), 1, [Ca(MCPA)2(H2O)2]·H2O, 2, and [Ca(TCPA)2(H2O)3 ]·2H2O, 3 [HCPA = 3-氯苯氧基乙酸，HMCPA = 2-甲基-4-氯苯氧基乙酸，HTCPA = 2,4,6-三氯苯氧基乙酸]，已通过微波法合成，具有反应时间短的优点次、更低的能耗和更高的产品产量。结构已通过红外、元素分析和单晶 X 射线衍射表征。讨论了改变苯氧乙酸中氯取代基的数量和位置对晶体结构的影响。涉及Cl的空间位阻效应和形成O-H⋯Cl氢键的能力丰富了结构的多样性。TG 分析表明三种化合物的热稳定性为 3 >

  DOI：

  10.1080/00958972.2015.1126259
• 作为产物：
  描述：

  (3-氯苯氧基)乙酸乙酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 间氯苯氧乙酸
  参考文献：
  名称：

  1,3,4-Thiadiazol-2-amine 衍生物作为 Urotensin-II 受体 (UT) 拮抗剂

  摘要：

  DOI：

  10.1002/bkcs.10475
• 作为试剂：
  描述：

  2-氯-6,7-二氢-5H环戊[b]并吡啶 在 copper(l) iodide 、 间氯苯氧乙酸 、 potassium carbonate 、 戴斯-马丁氧化剂 、 间氯过氧苯甲酸 、 potassium hydroxide 、 N,N'-二甲基乙二胺 、 三溴氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 95.5h， 生成 1-(7-Hydroxy-7-methyl-5,6-dihydrocyclopenta[b]pyridin-2-yl)-6-methylsulfinyl-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
  参考文献：
  名称：

  一种吡唑酮并嘧啶类化合物、其制备方法及应用

  摘要：

  本发明公开了一种吡唑酮并嘧啶类化合物、其制备方法及应用。本发明提供了一种如式I所示的吡唑酮并嘧啶类化合物，该类化合物对WEE1激酶的抑制活性较佳。

  公开号：

  CN112142748A

文献信息

• DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160221965A1

  公开（公告）日：2016-08-04

  The present application relates to novel 2,5-disubstituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

  本申请涉及新颖的2,5-二取代6-(三氟甲基)嘧啶-4(3H)-酮衍生物，其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管、肾脏、炎症和纤维化疾病。
• The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors
  作者：Ting Li、Guyue Liu、Hongcai Li、Xinmei Yang、Yongkui Jing、Guisen Zhao

  DOI：10.1016/j.bmc.2012.02.011

  日期：2012.4

  detoxifies chemotherapeutic agents in cancer cells. Ethacrynic acid (EA) is a weak GSTpi inhibitor. Structure modifications were done to improve the ability of EA to inhibit GSTpi activity. Eighteen EA thiazole derivatives were designed and synthesized. Compounds 9a, 9b and 9c with a replacement of carboxyl group of EA by a heterocyclic thiazole exhibited improvement over EA to inhibit GSTpi activity.

  谷胱甘肽S-转移酶pi（GSTpi）是II期酶，可保护细胞免于死亡，并清除癌细胞中的化学治疗剂。乙炔酸（EA）是一种弱的GSTpi抑制剂。进行结构修饰以提高EA抑制GSTpi活性的能力。设计并合成了18种EA噻唑衍生物。用杂环噻唑取代EA的羧基的化合物9a，9b和9c显示出相对于EA的改善，以抑制GSTpi活性。
• [EN] IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE L'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE JAK
  申请人：ALMIRALL SA

  公开号：WO2011076419A1

  公开（公告）日：2011-06-30

  New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  新的咪唑吡啶衍生物具有化学结构式(I)所示；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• Phenylalanine derivatives enhancing intestinal absorption of insulin in mice.
  作者：YUSUKE AMINO、KAZUHIRO KAWADA、KOJI TOI、IZUMI KUMASHIRO、KOJI FUKUSHIMA

  DOI：10.1248/cpb.36.4426

  日期：——

  The adjuvant effect of N-acyl-L-and D-phenylalanine derivatives on intestinal absorption of insulin was investigated in normal mice. The correlation between the chemical structural properties of the N-acyl moiety and the absorption-promoting activity was estimated from the glucose concentrations and the insulin levels in the blood of mice after oral combined administration of insulin and adjuvant. The chemical structural properties of N-acyl-phenylalanine derivatives necessary for adjuvant effect on intestinal absorption of insulin were as follows. 1. An aromatic ring is present, separated by two atoms from the acyl carbonyl group. 2. Either of X or Y is oxygen or X-Y is a double bond in Fig.2. 3. The N-acyl moiety has small hydrophobic substituents, such as F, Cl, or Me at Rα, Rβ, Rη and has an appropriate hydrophilic-hydrophobic balance of the overall molecule. The use of these agents to enhance insulin absorption offers the possibility of a new approach to oral insulin therapy.

  研究了N-酰基-L-和D-苯丙氨酸衍生物对正常小鼠胰岛素肠道吸收的辅助效应。根据小鼠口服胰岛素和辅料联合给药后的血糖浓度和胰岛素水平，推测了N-酰基部分的化学结构性质与促吸收活性之间的相关性。N-酰基-苯丙氨酸衍生物对胰岛素肠道吸收具有辅效应的化学结构性质如下：1. 芳环存在，与酰基羰基相隔两个原子。2. 图2中的X或Y之一为氧，或者X-Y是双键。3. N-酰基部分具有较小的疏水取代基，如F、Cl或Me在Rα、Rβ、Rη位置，并且整个分子具有适当的亲水-疏水平衡。利用这些制剂增强胰岛素吸收，为口服胰岛素治疗提供了新的途径。
• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193034A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾病和症状的化合物、组合物和方法。